Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Alto Neuroscience, Inc. ( (ANRO) ) has issued an announcement.
On June 26, 2025, Alto Neuroscience announced positive pharmacodynamic results from its exploratory Phase 2 proof-of-concept trial of ALTO-203, a non-stimulant compound targeting major depressive disorder patients with elevated anhedonia. The trial demonstrated ALTO-203’s potential in improving attention and wakefulness, with significant reductions in EEG theta/beta ratio, a biomarker for attentional control. These findings align with previous Phase 1 results and suggest ALTO-203’s promise as a treatment for neuropsychiatric conditions with impaired sleep and attention, reinforcing Alto’s precision psychiatry approach.
The most recent analyst rating on (ANRO) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Alto Neuroscience, Inc. stock, see the ANRO Stock Forecast page.
Spark’s Take on ANRO Stock
According to Spark, TipRanks’ AI Analyst, ANRO is a Neutral.
Alto Neuroscience, Inc. faces significant financial challenges with zero revenue, increasing losses, and negative cash flows, reflecting in a low financial performance score. Despite some technical indicators suggesting short-term upward momentum, the stock’s valuation remains risky due to a negative P/E ratio and lack of dividends, resulting in an overall low stock score.
To see Spark’s full report on ANRO stock, click here.
More about Alto Neuroscience, Inc.
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on developing novel precision medicines for neuropsychiatric disorders. The company utilizes its Precision Psychiatry Platform™ to measure brain biomarkers, aiming to create personalized and effective treatment options for conditions such as bipolar depression, major depressive disorder, treatment-resistant depression, and schizophrenia.
Average Trading Volume: 257,171
Technical Sentiment Signal: Sell
Current Market Cap: $69.58M
Find detailed analytics on ANRO stock on TipRanks’ Stock Analysis page.